Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd. director Raymond George Hill received a corrected grant of 1,319,996 stock options on November 11, 2026, replacing the 942,854 options reported originally. The options vest in equal monthly installments over four years beginning on the exercisable date, carry a U.S.-dollar exercise price of $0.0260 per share, and expire November 10, 2036. The reported post-transaction option position was 1,593,103 shares.
Addex Therapeutics Ltd. director Vincent Michael Lawton’s stock-option grant is corrected to 1,885,708 options, granted November 11, 2026; the original Form 4 reported 942,854. The options have an exercise price of $0.026 per share, and each option gives the right to buy one ADXN share listed on SIX Swiss Exchange. They vest in equal monthly installments over four years beginning on the exercisable date. Following the grant, Lawton’s direct stock-option position covered 2,387,306 shares.
Addex Therapeutics Ltd. director Vincent Michael Lawton received a grant of 942,854 stock options on November 11, 2026, each exercisable for one ADXN share at an exercise price of $0.026 per share. The options vest in equal monthly installments over four years beginning at the exercisable date. His reported stock-option holdings after the grant were 1,444,452. The exercise price reflects conversion from CHF at $1.1995 per CHF 1.00 as of November 11, 2026.
Addex Therapeutics Ltd. (ADXN) Chief Medical Officer and director Roger Mills received an award of 942,854 stock options on November 11, 2026. Each option gives the right to purchase one share at an exercise price of $0.026. The options vest in equal monthly installments over four years beginning on the exercisable date and expire November 10, 2036. The reported total after the award was 992,854 stock options.
Addex Therapeutics Ltd. (ADXN) director Raymond George Hill was granted 942,854 stock options on November 11, 2026. Each option gives the right to purchase one ADXN share at an exercise price of $0.0260 per share. The options vest in equal monthly installments over four years beginning on the exercisable date and expire November 10, 2036. Following the award, Hill reported holding 1,215,961 stock options.
Addex Therapeutics Ltd. (ADXN) granted its principal accounting officer, Lenaic Nathanael Teyssedou, 3,771,415 stock options on November 11, 2026. The options have an exercise price of $0.0260 per share, reported in U.S. dollars after conversion from CHF at $1.1995 per CHF 1.00. They vest in equal monthly installments over four years beginning at the exercisable date; each option gives the right to purchase one ADXN share. The reported total following the grant was 4,374,323.
Addex Therapeutics Ltd. director Jason Raleigh Nunn received a grant of 942,854 stock options on November 11, 2026, bringing his directly held options after the grant to 992,854. The options have an exercise price of $0.026 per share and vest in equal monthly installments over four years beginning at the exercisable date. Each option gives the right to purchase one ADXN share listed on SIX Swiss Exchange.
Addex Therapeutics Ltd. director Isaac Manke received 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share. The options vest in equal monthly installments over four years beginning at the exercisable date. Each option grants the right to purchase one ADXN share listed on SIX Swiss Exchange, and the options expire November 10, 2036. The reported post-grant stock-option position was tied to 992,854 underlying shares.
Addex Therapeutics Ltd. (ADXN) Chief Executive Officer Timothy Mark Dyer received an award of 18,857,075 stock options on November 11, 2026. Each option grants the right to purchase one ADXN share at a reported exercise price of $0.026 per share. The options vest in equal monthly installments over four years beginning at the exercisable date and expire November 10, 2036. His reported position after the award was 22,226,871 shares underlying options.
Addex Therapeutics Ltd. announced that its spin-out Neurosterix closed a $105 million Series B financing from a syndicate of life-science investors. Addex did not participate; its equity interest represents 8.5% of Neurosterix’s issued capital at a valuation of $18.6 million.
The financing proceeds will support mainly the planned Phase 2 clinical development of NTX-253, a selective muscarinic M4 positive allosteric modulator for schizophrenia, and Neurosterix’s broader pipeline. Neurosterix has completed Phase 1 studies of NTX-253, with data supporting advancement into larger-scale Phase 2 studies. Its pipeline also includes NTX-819 for mood and anxiety disorders and NTX-529 for additional psychosis- and mood-related disorders.